Premium
A phase II evaluation of adriamycin and cis‐platinum in hormone resistant prostate cancer
Author(s) -
Citrin Dennis L.,
Hogan Tom F.
Publication year - 1982
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19820715)50:2<201::aid-cncr2820500205>3.0.co;2-7
Subject(s) - medicine , prostate cancer , prostatic acid phosphatase , cancer , phases of clinical research , prostate , toxicity , oncology , urology , alkaline phosphatase , acid phosphatase , enzyme , biochemistry , chemistry
Twenty‐five patients with metastatic prostate cancer were treated with a combination of Adriamycin 50 mg/m 2 and cis‐platinum (CDDP) 50 mg/m 2 every three weeks. Response was evaluated using radioisotope bone scan, serum acid phosphatase levels, and clinical status. Response rates of 6% bone, 21% acid phosphatase, and 24% clinical status were noted. Major toxicity was gastrointestinal (due to CDDP). Treatment was well tolerated even in patients with extensive bone metastases and prior irradiation. Using the response criteria described here, patients with metastatic prostate cancer without measurable soft tissue disease are eligible for Phase II and III study.